STVN Stevanato Group S.p.A.
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass converting machines; and after-sales services, such as line optimization and line conversions, training, logistics, spare parts and maintenance services. It also provides contract development and manufacturing services for customer-owned drug delivery devices. The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug products, glass packaging, and fill and finish contract manufacturers. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.…
Industry Peers
Medical Instruments & SuppliesKey Statistics
About Stevanato Group (NYSE: STVN)
›
Stevanato Group (NYSE: STVN) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 6,010 employees.
The shares were at 15.93 USD on 19 November 2026, down 23.3% over 52 weeks. Its 52-week range is 12.06 USD to 24.01 USD: the price is 33.7% below the high and 32.1% above the low.
At a market capitalisation of 4.35B USD, it trades at 27.0 times trailing earnings and 22.0 times forward earnings. The median trailing P/E of its 19 largest Medical Instruments & Supplies peers is 49.2, a discount of 45% for STVN. It pays a dividend yielding 0.40% (it pays out 11% of its earnings), against a median of 0.93% among the dividend payers in that peer group.
Stevanato Group reports return on equity of 9.4%, an operating margin of 18.0% and revenue up 7.6% year over year.
Its debt exceeds its cash by 355.42M EUR, a debt-to-equity ratio of 0.32. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 12 analysts cover the stock, with an average rating of Buy; their mean price target of 19.46 USD is 22.1% above the current price. The next earnings report is expected on 3 March 2027.